Federica Forbici Selected Research

Maraviroc

1/2013

The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Federica Forbici Research Topics

Disease

6	Viremia 01/2022 - 10/2007
5	Acquired Immunodeficiency Syndrome (AIDS) 07/2009 - 02/2004
3	Disease Progression 01/2007 - 07/2005
2	HIV Infections (HIV Infection) 03/2022 - 02/2004
2	Infections 01/2020 - 11/2011
1	Progressive Multifocal Leukoencephalopathy 01/2022
1	Malnutrition (Nutritional Deficiencies) 08/2005

Drug/Important Bio-Agent (IBA)

5	Pharmaceutical PreparationsIBA 03/2022 - 07/2005
4	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2005
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 10/2007
2	Antiviral Agents (Antivirals)IBA 04/2014 - 08/2005
2	Protease Inhibitors (Protease Inhibitor)IBA 07/2009 - 07/2005
1	IntegrasesIBA 03/2022
1	pembrolizumabIBA 01/2022
1	Biological ProductsIBA 01/2020
1	Maraviroc FDA Link 01/2013
1	tipranavir FDA Link 07/2009
1	Peptide Hydrolases (Proteases)FDA Link 07/2009
1	efavirenz (Sustiva)FDA Link 05/2006
1	abacavir (Ziagen)FDA Link 05/2006
1	Lamivudine (Epivir)FDA Link 05/2006

Therapy/Procedure

3	Therapeutics 06/2014 - 02/2004
2	Highly Active Antiretroviral Therapy (HAART) 04/2014 - 10/2007
1	Salvage Therapy 07/2009
1	Aftercare (After-Treatment) 01/2007